As such, Novo Nordisk ended its collaboration with Hims & Hers over concerns of illegal mass compounding and deceptive ...

Novo Nordisk has ended a partnership with telehealth company Him & Hers, after launching the collaboration less than two ...

Novo Nordisk alleged that Hims & Hers is putting patient safety at risk by selling compounded versions of Wegovy. Novo's ...

Hims & Hers delivered record Q1 results and expanded into Europe with the Zava acquisition. Click here to see why HIMS stock ...

Novo Nordisk said Monday it will end its collaboration with Hims & Hers that offered the weight loss medication Wegovy for patients who have a prescription for the medication but no insurance coverage ...

The home builder says it has worked to lower its build times and reduce direct construction costs as it navigates softer market conditions. The airline's relisting comes against the backdrop of an ...

Teladoc Health stock price surged by over 14% on Monday, its best single-day gain since April 9. What next for the TDOC share ...

The Danish maker of obesity drugs abruptly ended a Wegovy distribution deal with the telehealth firm, citing allegations ...

On Stocktwits, 24-hour message volume around HIMS soared 6,717% — the fifth highest among healthcare stocks. It was the top trending ticker on the platform late Monday.

On Monday, major U.S. indices ended the day in the green with the Dow Jones Industrial Average rising 0.9% to 42,581.78, and the S&P 500 gaining nearly 1% to 6,025.17.

The Danish pharmaceutical said it was ending the partnership because Hims is selling and promoting a cheaper copycat of its ...